Related Experiment Video
Updated: Feb 7, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Vanadocene dichloride inhibits cell proliferation by targeting Aurora B
Tzu-Chia Ting1, Meng-Ya Chang, Tzu-Yen Hsu
1Department of Molecular Biology and Human Genetics, Tzu-Chi University, Hualien, Taiwan. cjchang@mail.tcu.edu.tw.
Abstract:
Vanadocene dichloride (VDC) was shown to exhibit antitumor properties against a wide spectrum of tumor cell lines. Many studies have been carried out to reveal the bioactivities of VDC and the interaction mechanism of VDC with biological molecules in test tubes. One of the bioactivities of VDC is to arrest the cell cycle at the G2/M phase. However, its underlying mechanisms of action and cytotoxicity profile are still not fully understood. HeLa cells were used in this study, and the IC50 value of VDC was 8.61 μM after a 24-hour treatment. We used an immunofluorescence staining method to analyze the morphology of cells in the mitosis stage to elucidate what defects caused cell arrest in mitosis. Chromosomal misalignment was found to be the major phenotype. One of the proteins responsible for chromosome alignment at the metaphase is Aurora B kinase. Results of immunoblotting assay showed that Aurora B kinase activity was inhibited by VDC treatment. More than 50% of the Aurora B activity was inhibited when cells were treated with VDC at a concentration of 6.25 μM. That VDC was able to induce defects in chromosomal alignment at the metaphase by inhibiting the activity of Aurora B kinase is an important mechanism of VDC to be developed as an antitumor agent.
Insights
Vanadocene dichloride (VDC) shows antitumor potential by arresting cancer cells in mitosis. It inhibits Aurora B kinase, leading to chromosomal misalignment and cell death, offering a novel therapeutic strategy.
Area of Science:
- Oncology
- Cell Biology
- Biochemistry
Background:
- Vanadocene dichloride (VDC) exhibits broad-spectrum antitumor properties.
- VDC is known to arrest the cell cycle at the G2/M phase.
- The precise mechanisms of VDC's action and cytotoxicity remain incompletely understood.
Purpose of the Study:
- To investigate the mechanism of VDC-induced cell cycle arrest in HeLa cells.
- To identify the specific defects in mitosis caused by VDC treatment.
- To elucidate the role of Aurora B kinase in VDC's antitumor activity.
Main Methods:
- HeLa cells were treated with VDC, and the IC50 value was determined.
- Immunofluorescence staining was employed to analyze mitotic cell morphology.
- Immunoblotting assays were used to assess Aurora B kinase activity.
Main Results:
- VDC demonstrated an IC50 of 8.61 μM in HeLa cells after 24-hour treatment.
- Chromosomal misalignment was identified as the primary defect in VDC-treated cells.
- VDC significantly inhibited Aurora B kinase activity, with over 50% inhibition at 6.25 μM.
Conclusions:
- VDC induces mitotic defects, specifically chromosomal misalignment, in cancer cells.
- Inhibition of Aurora B kinase activity is a key mechanism underlying VDC's antitumor effects.
- Targeting Aurora B kinase via VDC presents a promising avenue for cancer therapy development.
Related Concept Videos
Feedback Inhibition
Cells Coordinate Growth and Proliferation
Abnormal Proliferation
Enzyme Inhibition
Target Cell Response to Hormones
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...
Inhibition of Cdk Activity

